SEQUENTIAL ANTITHYMOCYTE GLOBULIN & AMIFOSTINE FOR MDS

骨髓增生异常综合征是一种异质性的克隆性造血疾病，其特征是造血功能低下，进行性外周细胞减少，并有发展为急性髓系白血病的倾向。目前仍在研究的MDS的新治疗方案包括氨磷汀和抗胸腺球蛋白（ATG）。尽管氨磷汀和ATG作为单独的药物都显示出改善细胞减少和骨髓细胞计数的效果，但有许多用这些药物治疗的患者在一种或多种细胞系中没有反应或反应很小。细胞减少和发展为AML的原因可能是多因素的。本研究假设两种药物联合治疗——每一种药物都有不同的作用机制——可能在改善外周计数和减少疾病进展方面具有协同作用。

The myelodysplastic syndrome is a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, progressive peripheral cytopenias, and a tendency to progress to acute myeloid leukemia. New therapeutic options in MDS which are still under investigation include amifostine and antithymocite globulin (ATG). Although both amifostine and ATG have shown effects as individual agents in improving cytopenias and, perhaps, marrow blast count, there have been many patients treated with these agents who had none or minimal response in one or more cell lines. The cause of cytopenias and progression to AML is likely multifactorial. This study hypothesizes that treatment with the combination of the two agents -- each of which has a different mechanism of action -- may be synergistic in improving peripheral counts and reducing disease progression.